Researchers link GLP1 agonists to depression risk in some users and call for personalized prescribing based on genetic testing. A study published in Current Neuropharmacology reveals a potential link between Glucagon-like Peptide-1 (GLP-1) receptor agonists, commonly used in drugs like Ozempic, and an increased risk of depression and suicidal ideation (SI). Using advanced pharmacogenomic computational […]